These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17502517)

  • 41. Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema.
    Lee J; Ra H; Baek J
    Indian J Ophthalmol; 2019 Dec; 67(12):2058-2059. PubMed ID: 31755455
    [No Abstract]   [Full Text] [Related]  

  • 42. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
    Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypertrophic osteoarthropathy associated with docetaxel treatment.
    Tas F; Aydiner A; Tenekeci N; Karadeniz A; Sakar B; Topuz E
    Clin Oncol (R Coll Radiol); 2001; 13(2):145-6. PubMed ID: 11373880
    [No Abstract]   [Full Text] [Related]  

  • 44. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment.
    Ota M; Nishijima K; Sakamoto A; Murakami T; Takayama K; Horii T; Yoshimura N
    Ophthalmology; 2010 Oct; 117(10):1996-2002. PubMed ID: 20723993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of fingolimod-associated macular edema.
    Chui J; Herkes GK; Chang A
    JAMA Ophthalmol; 2013 May; 131(5):694-6. PubMed ID: 23538612
    [No Abstract]   [Full Text] [Related]  

  • 48. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
    Miller KD
    Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
    [No Abstract]   [Full Text] [Related]  

  • 49. Topical dorzolamide therapy for taxane-related macular oedema.
    Ehlers JP; Rayess H; Steinle N
    Eye (Lond); 2013 Jan; 27(1):102-4. PubMed ID: 23154489
    [No Abstract]   [Full Text] [Related]  

  • 50. Cystoid macular edema induced by nab-paclitaxel.
    Tanaka Y; Bando H; Hara H; Ito Y; Okamoto Y
    Breast Cancer; 2015 May; 22(3):324-6. PubMed ID: 22592399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
    Camidge DR; Kunkler IH
    Clin Oncol (R Coll Radiol); 2000; 12(4):272-3. PubMed ID: 11005698
    [No Abstract]   [Full Text] [Related]  

  • 52. [A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
    Marutaka M; Suguri T; Miyake M; Yoshimura K
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2137-9. PubMed ID: 16352945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 54. Cystoid macular edema associated with fingolimod use for multiple sclerosis.
    Afshar AR; Fernandes JK; Patel RD; Ksiazek SM; Sheth VS; Reder AT; Hariprasad SM
    JAMA Ophthalmol; 2013 Jan; 131(1):103-7. PubMed ID: 23307220
    [No Abstract]   [Full Text] [Related]  

  • 55. Intravitreous ranibizumab (lucentis) for radiation maculopathy.
    Finger PT; Chin KJ
    Arch Ophthalmol; 2010 Feb; 128(2):249-52. PubMed ID: 20142553
    [No Abstract]   [Full Text] [Related]  

  • 56. A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer.
    Scholz U; Lück HJ; Canzler U; Robner D; Kühnle H
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):44-6. PubMed ID: 11098492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
    Meden H; Beneke A; Hesse T; Novophashenny I; Wischnewsky M
    Anticancer Res; 2001; 21(2B):1301-5. PubMed ID: 11396203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
    Querques G
    Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
    [No Abstract]   [Full Text] [Related]  

  • 59. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
    Matsumoto Y; Freund KB; Peiretti E; Cooney MJ; Ferrara DC; Yannuzzi LA
    Retina; 2007; 27(4):426-31. PubMed ID: 17420693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival after brain metastases from breast cancer in the trastuzumab era.
    Kirsch DG; Ledezma CJ; Mathews CS; Bhan AK; Ancukiewicz M; Hochberg FH; Loeffler JS
    J Clin Oncol; 2005 Mar; 23(9):2114-6; author reply 2116-7. PubMed ID: 15774813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.